FDA Approves First Drug for Friedreich’s Ataxia
Published on in CHOP News
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Friedreich's Ataxia Program News and Updates
1 - 8 of 8
Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research
Published on in CHOP News
The Friedreich’s Ataxia Center of Excellence at CHOP was awarded $1.275 million by the Friedreich’s Ataxia Research Alliance, Hamilton and Finneran families and the CureFA Foundation
CHOP Joins Worldwide Consortium to Study Biomarkers, Natural History for Freidreich’s Ataxia
Published on in CHOP News
This consortium will conduct the most extensive neuroimaging study for Freidreich's ataxia to date.
CHOP Embarking on Interventional Trial
To date, the effects of exercise have not been studied in children with Friedreich’s Ataxia – until now.
Read moreIn Pursuit of Cure for a Rare Degenerative Disease
Published on in Children's View
A rare degenerative disease strikes during childhood. A multimillion-dollar gift is fueling CHOP scientists’ search for a cure.
Friedreich’s Ataxia: Taking Shots on Goal for a Rare Disease
Published on in Neurosciences Update, International Update
Researchers rarely use the word "cure" when studying a rare disease with no approved therapies. At the Friedreich's Ataxia Center of Excellence, the word "cure" is now in the lexicon.
Amazing Grace
Published on in Children's View
The new Friedreich’s Ataxia Center of Excellence gives hope and education to Grace Haupt and patients just like her.
$3.25 Million Gift Creates Friedreich’s Ataxia Center of Excellence
Published on in CHOP News
Donations from Friedreich’s Ataxia Research Alliance and the Hamilton and Finneran Families helps launch Penn Medicine/CHOP Center to improve research and care for Friedreich's Ataxia, a rare, degenerative disease.